Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

BACKGROUND. Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. MATERIALS AND METHODS. This prospective, multi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Capdevila, Jaume, Teulé, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, García‐Carbonero, Rocío, Dotor, Emma, Matos, Ignacio, Custodio, Ana, Casanovas, Oriol, Salazar, Ramon
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2018
Fag:
Endocrinology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324631/
https://ncbi.nlm.nih.gov/pubmed/29794066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0622
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker